We report the first case of a patient with hepatitis C virus (HCV) infection and idiopathic thrombocytopenic purpura (ITP), who later developed acquired amegakaryocytic thrombocytopenia (AAMT), with autoantibodies to the thrombopoietin (TPO) receptor (c-Mpl). A 64-year-old woman, with chronic hepatitis C, developed severe thrombocytopenia and was diagnosed with ITP. She died of liver failure. Autopsy revealed cirrhosis and liver carcinoma. In the bone marrow, a marked reduction in the number of megakaryocytes was observed, while other cell lineages were preserved. Therefore, she was diagnosed with AAMT. Additionally, autoantibodies to c-Mpl were detected in her serum. Autoantibodies to c-Mpl are one of the causes of AAMT, acting through inhibition of TPO function, megakaryocytic maturation, and platelet formation. HCV infection induces several autoantibodies. HCV infection might also induce autoantibodies to c-Mpl, resulting in the development of AAMT. This mechanism may be one ISSN 2219ISSN -2840 of the causes of thrombocytopenia in patients with HCV infection.
Abstract
We report the first case of a patient with hepatitis C virus (HCV) infection and idiopathic thrombocytopenic purpura (ITP), who later developed acquired amegakaryocytic thrombocytopenia (AAMT), with autoantibodies to the thrombopoietin (TPO) receptor (c-Mpl). A 64-year-old woman, with chronic hepatitis C, developed severe thrombocytopenia and was diagnosed with ITP. She died of liver failure. Autopsy revealed cirrhosis and liver carcinoma. In the bone marrow, a marked reduction in the number of megakaryocytes was observed, while other cell lineages were preserved. Therefore, she was diagnosed with AAMT. Additionally, autoantibodies to c-Mpl were detected in her serum. Autoantibodies to c-Mpl are one of the causes of AAMT, acting through inhibition of TPO function, megakaryocytic maturation, and platelet formation. HCV infection induces several autoantibodies. HCV infection might also induce autoantibodies to c-Mpl, resulting in the development of AAMT. This mechanism may be one
INTRODUCTION
Thrombocytopenia occurs frequently in patients with chronic hepatitis C. The causes of thrombocyto penia in patients with chronic hepatitis C are multiple, such as hypersplenism, immunological processes, and decreased thrombopoietin (TPO) level [1, 2] . Acquired amegakaryocytic thrombocytopenia (AAMT) is one of the causes of severe thrombocy topenia and is characterized by a marked reduction in the number of megakaryocytes, with preserved hematopoiesis of the other lineages in the bone marrow [3] . The exact mechanisms of AAMT have not been fully elucidated. However, the defect of TPO receptor (cMpl) expression due to c-Mpl gene mutation is the major cause of congenital amegakaryocytic thrombocytopenia [4] . Furthermore, patients with systemic lupus erythematosus (SLE) and systemic sclerosis who have autoantibodies to cMpl develop AAMT [5, 6] . TPO, produced mainly by hepatocytes, binds to cMpl on hematopoietic stem cells and megakaryocytes, and promotes all stages of platelet production, from the proliferation and differentiation of megakaryocytes to megakaryocytic maturation and platelet formation [1] . Thus, autoantibodies to cMpl may be one of the causes of AAMT, through inhibiting TPO function. AAMT with autoantibodies to cMpl has not previously been reported in patients with hepatitis C virus (HCV) infection.
Here, we report the first case of a patient with HCV infection and idiopathic thrombocytopenic purpura (ITP), who later developed AAMT with autoantibodies to cMpl.
CASE REPORT
A 64yearold woman was admitted with the chief Ichimata S et al. AAMT associated with HCV infection /μL). At that time, she received interferon therapy, but the HCV infection persisted. At the age of 51 and 52, liver biopsy and bone marrow aspirations were performed, respectively. Liver biopsy specimens revealed periportal mild inflammatory cell infiltration and fibrosis (Modified Histological Activity Index: activity was 5/18, fibrosis was 1/6; Figure 1A and B). The clot section of the bone marrow aspirate showed no significant change, and the number of megakaryocytes was within the normal range. Although the plateletassociated IgG (PA IgG) was not measured, she was diagnosed with ITP ( Figure  1C ). At the age of 61, liver cancer was detected, using computed tomography and magnetic resonance imaging, and she received transcatheter arterial chemoembolization (TACE) on several occasions. On the most recent admission, her liver cancer was found to be enlarged and ascites and pleural effusion had increased. Laboratory data are shown in Table  1 . Her laboratory data indicated hepatic dysfunction, remnants of liver cancer and thrombocytopenia. On day 15 of her admission, her general condition deteriorated, and she died of liver failure. An autopsy was performed.
At autopsy, she showed generalized jaundice and purpura in the anterior chest wall. Ascites (2600 mL) and pleural effusion (left: 100 mL, right: 3400 mL) were observed. Liver weight was 660 g, indicating severe atrophy. The cut surface of the liver showed diffuse micronodular cirrhosis with a dark green nodule (15 mm × 15 mm) in the left lobe, and a yellow, partly reddish or green, lesion with an irregular margin (70 mm × 50 mm) in the right lobe ( Figure 2A ). Spleen weight was 240 g, indicating mild enlargement. Varicose veins were observed in the lower esophagus, stomach, and rectum.
Histopathologically, liver specimens showed diffuse small regenerative nodules with fibrous septum and septal mild mononuclear cell infiltration ( Figure 2B ). The right lobe lesion was mainly composed of two components: hepatocellular carcinoma with bile production ( Figure 2C ) and adenocarcinoma with mucin production ( Figure 2D) . Therefore, the diagnosis of combined hepatocellularcholangiocarcinoma was made. There were no viable tumor cells in the left lobe lesion, compatible following TACE treatment for liver carcinoma. Microscopic metastases were observed in both lungs. Bone marrow specimens showed slight hypocellularity (30%40%), with a myeloid to erythroid ratio: 3 to 1, and a marked reduction in the number of megakaryocytes, < 1 megakaryocyte/10 high power fields ( Figure 2E ). Immunostaining for CD41 revealed scattered small megakaryocytes ( Figure 2F ). Other lineages of hematopoietic cells were preserved, and myelofibrosis, dysplasia, and metastatic lesions were not observed. Spleen specimens showed mild congestion without extramedullary hematopoiesis. Characteristic histopathological findings of the spleen in patients with ITP, such as an increase of secondary follicles with welldelineated germinal centers, an expansion of a follicular marginal zone of the white pulp and a diffuse proliferation of foamy histiocytes, were not obvious in this patient. There was no definite lesion in the thyroid.
Next, we evaluated serum TPO levels at the time of her last admission using an enzymelinked immunosorbent assay (ELISA) kit (Quantikine, R&D Systems, Minneapolis, United States) according to the manufacturer's protocol. The serum TPO level of the patient was 54 pg/mL, and the serum TPO levels of two healthy individuals without HCV infection were 27 and paraneoplastic autoimmunity were considered to be restrictive causes of her thrombocytopenia because she showed thrombocytopenia before development of her liver cirrhosis and liver cancer. In addition, her serum TPO level was preserved at the time of her last admission. Yet ITP was one of the causes of her thrombocytopenia. However, characteristic histopathological findings of the spleen in patients with ITP were not obvious in this patient at the time of autopsy. It is unclear when autoantibodies to cMpl started to be produced in this patient. The patient showed a normal number of megakaryocytes at least ten years before her death, that is, ten years after the onset of thrombocytopenia. This finding is compatible with ITP. Therefore, autoantibodies to cMpl might have pg/mL and 37 pg/mL (mean 32 pg/mL). In addition, the presence or absence of antiTPO receptor (cMpl) autoantibodies was determined, using Human anti thrombopoietin receptor (CMPL) autoantibodies IgG ELISA kit (CUSABIO, Wuhan, China), according to the manufacturer's protocol. The serum sample of the patient at the time of her last admission was positive for anticMpl antibodies, compared to the negative results of the sera of two healthy individuals without HCV infection.
DISCUSSION
In the current case, AAMT associated with autoanti bodies to cMpl was considered to be one of the major causes of her severe thrombocytopenia. Hypersplenism developed after the diagnosis of ITP and the patient subsequently developed AAMT. It is possible that autoantibodies to cMpl had already been produced at the time of the ITP diagnosis. Kuwana et al [5] reported that autoantibodies to cMpl are detected in approximately 8% of ITP patients. Thus, patients with autoantibodies to cMpl might develop ITP at an early stage, and then develop AAMT during the course of the disease. This hypothesis is summarized in Figure 3 . The receptor cMpl is expressed in the megakaryocytic lineage from late progenitors to platelets, and platelets display high-affinity receptors for TPO [7] . Therefore, even if autoantibodies to cMpl had been produced at an early stage, most of the autoantibodies would have been absorbed with cMpl on platelets, and the proliferation and differentiation of megakaryocytes would not have been severely impaired. Thus, the number of megakaryocytes in bone marrow would be relatively well preserved and the patient's bone marrow may show a histopathology compatible with ITP. After a sufficient reduction in the number of platelets, AAMT then could then develop because autoantibodies to cMpl start to bind to cMpl on megakaryocytes and progenitor cells, inhibiting their development and maturation. Hoffman et al [8] . described a patient with ITP who later developed AAMT associated with antibodies that suppressed the colony formation of megakaryocytes [8] . HCV infection might have induced autoantibodies to cMpl in the current patient. Autoantibodies to cMpl are not detected in healthy controls [5] . In patients with HCV infection, several autoantibodies are produced, such as antinuclear antibodies, antismooth muscle antibodies, organspecific autoantibodies, and anti platelet antibodies [1] . In addition, antiplatelet IgG antibodies are detected in 26.3% of patients with HCV infection, showing a higher prevalence compared to healthy controls [9] . These mechanisms may play a role in the development of AAMT, with autoantibodies to cMpl in patients with HCV infection. However, interferon therapy induces several autoantibodies to multiple organ systems, such as antithyroid antibodies, autoantibodies indicative of autoimmune hepatitis, and antiplatelet autoantibodies [10] , and exhibits side effects of developing autoimmune diseases. Autoimmune thrombocytopenia sometimes occurs both during and after interferon therapy [11] . Thus, interferon therapy might have induced autoantibodies to cMpl in the current patient. We consider that interferon therapy did not play a significant role in the induction of autoantibodies to cMpl here because the patient's bone marrow had shown a normal number of megakaryocytes for ten years at least, following interferon therapy.
The current case provides a new perspective on thrombocytopenia in patients with HCV infection. AAMT with autoantibodies to cMpl may be one of the causes of thrombocytopenia in these patients. Some patients with HCV infectionassociated thrombocytopenia, for whom thrombopoietin receptor agonists have a weak effect, might have this condition. Further investigation will be necessary, especially concerning the relationship between AAMT with autoantibodies to cMpl and HCV infection.
AAMT with autoantibodies to cMpl can be one of the causes of thrombocytopenia in patients with chronic HCV infection.
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Case characteristics
A 64-year-old woman with hepatitis C virus (HCV) infection and idiopathic thrombocytopenic purpura presented with dyspnea.
Clinical diagnosis
Liver failure due to chronic hepatitis C. 
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